Atopic Dermatitis/Atopic Eczema – Unmet Need – Detailed, Expanded Analysis – Moderate To Severe Topical-Refractory Atopic Dermatitis (US/EU) – 2021

The approval of Dupixent has transformed the management of topical-refractory moderate to severe atopic dermatitis (AD), and the active, diverse AD pipeline is filled with compelling emerging options from several novel classes including IL-13 inhibitors, JAK inhibitors, and IL-31 inhibitors. In this report, we assess the commercial opportunity remaining in the topical-refractory moderate to severe AD space through a comprehensive analysis of dermatologists’ treatment goals; the key efficacy, safety / tolerability, and delivery attributes driving prescribing choice; the gaps in treatment left by current therapies; and the interplay of clinical and nonclinical attributes in determining the commercial potential of new AD products.

Questions Answered

  • What are the key treatment drivers and goals for topical-refractory moderate to severe AD? How do current therapies such as Dupixent perform against these key treatment drivers and goals?
  • What are the key opportunities for drug development in topical-refractory moderate to severe AD? Where do surveyed dermatologists perceive the largest gaps in the treatment of topical-refractory moderate to severe AD patients?
  • What trade-offs among queried clinical attributes and price are acceptable to U.S. and European dermatologists when considering whether to prescribe a hypothetical new AD therapy?

Content Highlights

Markets covered: United States, United Kingdom, France, Germany.

Primary research: Survey of 61 U.S. and 31 European dermatologists fielded in January 2021.

Key companies: Sanofi, Regeneron, LEO Pharma, Eli Lilly, Pfizer, AbbVie, Galderma.

Key drugs: Dupixent, cyclosporine, methotrexate, mycophenolate mofetil, azathioprine, prednisone.

Product Description

Unmet Need supports clinical development decisions by identifying key attributes and assessing areas of unmet need for a specific disease or subpopulation. Based on surveys with U.S. and European physicians, this report provides insight into key treatment drivers and goals, the performance of current therapies, and the remaining commercial opportunities. One market scenario is profiled in detail by Clarivate experts, and additional customized market scenarios can be evaluated with the corresponding TPP simulator.

Table of contents

  • Atopic Dermatitis/Atopic Eczema - Unmet Need - Detailed, Expanded Analysis - Moderate To Severe Topical-Refractory Atopic Dermatitis (US/EU) - 2021
    • Executive Summary
      • Unmet Need - Topical-Refractory Moderate to Severe Atopic Dermatitis - Executive Summary - March 2021
    • Introduction
      • Overview
      • Methodology
      • Rationale for Treatment Drivers and Goals Selection
        • Rationale for Drug Selection
          • Products for Atopic Dermatitis and Rationale for Drug Selection
      • Treatment Drivers and Goals
        • Key Findings: Attribute Importance
        • Relative Importance of Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Surveyed Dermatologists Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis
        • Importance of Efficacy Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Importance of Safety and Tolerability Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Importance of Nonclinical Factors to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Importance of Nonclinical Factors to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Key Findings: Stated vs. Derived Importance
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Stated vs. Derived Importance of Key Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Attributes to Prescribing Decisions in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
      • Product Performance Against Treatment Drivers and Goals
        • Key Findings
        • Overall Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Overall Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Mean Overall Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis: United States and Europe
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Efficacy Attributes: United States
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Efficacy Attributes: Europe
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Safety and Tolerability Attributes: United States
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Safety and Tolerability Attributes: Europe
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Convenience of Administration Attributes: United States
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Convenience of Administration Attributes: Europe
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Nonclinical Attributes: United States
        • Relative Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis Across Select Nonclinical Attributes: Europe
      • Assessment of Unmet Need
        • Key Findings: Unmet Need in Topical-Refractory Moderate to Severe Atopic Dermatitis
        • Surveyed Dermatologistsu2019 Satisfaction with the Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: United States
        • Surveyed Dermatologistsu2019 Satisfaction with the Performance of Key Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis on Efficacy, Safety and Tolerability, Convenience of Administration, and Nonclinical Factors: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Safety and Tolerability Attributes in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Topical-Refractory Moderate to Severe Atopic Dermatitis: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need Across Key Nonclinical Factors in Topical-Refractory Moderate to Severe Atopic Dermatitis: Europe
        • Key Findings: Unmet Need in Topical-Refractory Moderate to Severe Atopic Dermatitis and Related Indications
        • Surveyed Dermatologists' Ascribed Level of Unmet Need in Topical-Refractory Moderate to Severe Atopic Dermatitis and Related Indications: United States
        • Surveyed Dermatologists' Ascribed Level of Unmet Need in Topical-Refractory Moderate to Severe Atopic Dermatitis and Related Indications: Europe
      • Opportunity Analysis
        • Areas of Opportunity in the Topical-Refractory Moderate to Severe Atopic Dermatitis Market and Emerging Therapy Insights
          • Opportunity: Systemic Therapies That Are More Effective in Clearing Eczema and Reducing Itch
          • Opportunity: Additional Effective Therapies Offering a Good Safety and Tolerability Profile
          • Opportunity: Therapies Offering a Convenient Route of Administration
      • Target Product Profiles
        • Assessing Drug Development Opportunities
        • Target Product Profile Methodology
          • Attributes and Attribute Levels
          • Attributes of Key Current and Late-Phase Emerging Therapies for Topical-Refractory Moderate to Severe Atopic Dermatitis
        • Attribute Importance and Part-Worth Utilities
          • Topical-Refractory Moderate to Severe Atopic Dermatitis Target Product Profile: Attribute Importance
          • Percentage of Patients Achieving IGA of 0-1 and u2265 2-Unit Improvement at Week 16 (monotherapy)
          • Percentage of Patients with u2265 4-Unit Improvement in Pruritus NRS at Week 16 (monotherapy)
          • EASI-75 Responder Rate at Week 16 (monotherapy)
          • Monitoring Burden
          • Delivery Burden (route of administration and dosing frequency)
          • Overall Infection Risk Ratio Versus Placebo
          • Price per Treated Day
        • Conjoint Analysis-Based Simulation of a Market Scenario
          • Topical-Refractory Moderate to Severe Atopic Dermatitis Market Simulation: Share of Preference of Target Product Profiles Included in the Market Scenario
          • Topical-Refractory Moderate to Severe Atopic Dermatitis Market Simulation: Likelihood to Prescribe Target Product Profiles Included in the Market Scenario
          • Topical-Refractory Moderate to Severe Atopic Dermatitis Market Simulation: Target Product Profiles Included in the Market Scenario
      • Appendix
        • Key Abbreviations
        • Bibliography

    Login to access report